Featured Research

from universities, journals, and other organizations

Two-pronged approach successfully targets DNA synthesis in leukemic cells

Date:
February 24, 2014
Source:
The Rockefeller University Press
Summary:
A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice while sparing damage to normal blood cells, researchers have shown. Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues. Results of the new research indicate that there may be other ways to address leukemia while sparing the patient these side effects.

A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.

Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues.

In order to replicate, cells must make copies of their DNA, which is made up of building blocks called deoxyribonucleotide triphosphates (dNTPs). Cells can either make dNTPs from scratch (the "de novo" pathway) or by picking up the breakdown products of cells death (the "salvage" pathway). Caius Radu and colleagues at the University of California, Los Angeles now show that blocking the de novo pathway using thymidine causes leukemia cells to switch to the salvage pathway. This may explain why thymidine showed limited effectiveness as a single agent in clinical trials. Blocking both the de novo and salvage pathways was lethal for leukemic cells. The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway). Importantly, there was no significant toxicity to normal blood cell development. Why leukemic cells and normal blood cell precursors respond so differently to this treatment requires further investigation.

According to Radu, "this new dual targeting approach shows that we can overcome the redundancy in DNA synthesis in ALL cells and identifies a potential target for metabolic intervention in ALL, and possibly in other hematological cancers."

This interdisciplinary study not only advances our understanding of DNA synthesis in leukemic cells but also identifies targeted metabolic intervention as a new therapeutic approach in ALL. Clinical trials will be required to establish whether these promising findings will translate into a new therapeutic approach for ALL.


Story Source:

The above story is based on materials provided by The Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. A. Nathanson, A. L. Armijo, M. Tom, Z. Li, E. Dimitrova, W. R. Austin, J. Nomme, D. O. Campbell, L. Ta, T. M. Le, J. T. Lee, R. Darvish, A. Gordin, L. Wei, H.-I. Liao, M. Wilks, C. Martin, S. Sadeghi, J. M. Murphy, N. Boulos, M. E. Phelps, K. F. Faull, H. R. Herschman, M. E. Jung, J. Czernin, A. Lavie, C. G. Radu. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. Journal of Experimental Medicine, 2014; DOI: 10.1084/jem.20131738

Cite This Page:

The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224123636.htm>.
The Rockefeller University Press. (2014, February 24). Two-pronged approach successfully targets DNA synthesis in leukemic cells. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2014/02/140224123636.htm
The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224123636.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins